Lege Artis Medicinae

[LAMming ]

BÁNFALVI Attila

DECEMBER 20, 2010

Lege Artis Medicinae - 2010;20(12)

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Lecturis Salutem! Greetings to the Reader!]

KAPÓCS Gábor

Lege Artis Medicinae

[Portrait of a Great Physician – Imre Magyar was Born 100 Years Ago]

BUDA Béla

Lege Artis Medicinae

[Approaches to the identification and management of breakthrough disease in multiple sclerosis]

BENCSIK Krisztina

Lege Artis Medicinae

[Farewell to rosiglitazone: where to go?]

TAMÁS GYULA, KERÉNYI ZSUZSA

[The European Medicines Agency concluded that the marketing authorisation for all rosiglitazonecontaining medicines (Avandia, Avandamet, Avaglim) should be suspended across the European Union. The National Health Insurance Fund Administration in Hungary in a circular letter called the attention of GP’s to the necessity in getting the medical proposal (of an internist, endocrinologist or diabetologist) for substituting rosiglitazone to arrange a smooth modification of their treatment regimen. The review taking into account updated recommendations of the ADA-EASD and the Hungarian Diabetes Association summarises the potential drugs. The first line therapy of choice has to be starting with insulin. Pioglitazone might also be administered, with all known side effects of the glitazone family, e.g. congestive heart failure and bone fractures. Further alternatives are choosing the newer drugs of the incretin principle: the incretin mimetics (exenatid, liraglutid) and the incretin enhancers (sitagliptin, vildagliptin, saxagliptin). Beside their favourable profile of effect they do not have longterm follow up outcome studies and evidences for cardiovascular safety.]

Lege Artis Medicinae

[Misleading tumor markers in pulmonary carcinomas]

CIFRA János, BOGNER Barna, HELF László, SZÉKELYI Katalin, KÁLMÁN Endre, SÁPI Zoltán

[Lung cancers are the leading cause of tumorous mortality and the most frequent tumor in the 40- 70 years age range. The chance for cure in lung cancers is much higher in the early stage of disease so the early diagnosis has a paramount importance. Although many tumor markers are used in the diagnosis of malignant tumors, their specificity raise some doubts. The increased level of hCG is traditionally connected with choriocarcinomas and the CA 19-9 antigen is connected with gastrointestinal carcinomas. The production of hCG and CA19-9 is extremely rare but well established fenomenon in pulmonary carcinomas. In some cases of pulmonary cancers various tumor markers are produced, causing differential diagnostic difficulties. Through our cases and literature review we wanted to draw the attention of the organ unspecificity of these tumor markers.]

All articles in the issue

Related contents